TECH Stock Analysis — Bio-Techne
Sector: Healthcare
AI Verdict
Bio-Techne trades at 27x next year's earnings with a massive 290% EPS growth forecast, so you're getting a lot of growth for the price if its proprietary reagents keep labs locked in — but if that rebound slips, the valuation premium will evaporate fast.
Competitive Moat
Bio-Techne manufactures specialized proteins, antibodies, and reagents that are critical inputs for life sciences research and diagnostics, giving it a sticky customer base among labs and pharma companies. Its defensibility comes from proprietary product lines and deep integration into research workflows, making switching costly and risky for customers.
Summary
Bio-Techne is notable for a forecasted 290.4% jump in earnings next year, resetting its valuation after a period of sluggish growth.
Where It Stands
The stock returned 5.96% over the past year, trades at 27.0x next year's earnings (just above the healthcare median of 22x), and its RSI of 45.0 signals cooling momentum after a modest run.
Key Metrics
- RSI: 45 — Neutral
- Trailing P/E: 105.4x
- Forward P/E: 27.0x
- PEG Ratio: 0.37
- Earnings Growth: +2.9%
- Revenue Growth: +0.0%
- Market Cap: $8.4B
- Dividend Yield: 0.01%
- 1-Year Return: 5.96%
- 52-Week High: $72.16
- 52-Week Low: $46.05
Analyst Consensus
17 Buy · 6 Hold · 0 Sell (23 analysts)
Bull Case
With forward EPS growth consensus at 290.4%, the 27.0x forward P/E is cheap for the scale of earnings rebound analysts expect.
Bear Case
If the P/E reverts to the sector median of 22x instead of 27.0x, the stock could lose about 19% from current multiples even if growth materializes.
Catalyst to Watch
Watch for quarterly earnings to confirm the triple-digit EPS growth forecast — a miss could quickly deflate the premium multiple.